Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study

Acute Cardiac Care

Volumn 13, Issue 3, 2011, Pages 116-122

  Tousek, Petr ^a   Rokyta, Richard ^b   Tesarova, Jitka ^b   Pudil, Radek ^c   Belohlavek, Jan ^d   Stasek, Josef ^c   Rohac, Filip ^a   Widimsky, Petr ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Abciximab; Acute myocardial infarction; Cardiogenic shock; Outcome; Primary percutaneous coronary intervention

Indexed keywords

ABCIXIMAB;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLEEDING; BOLUS INJECTION; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART REINFARCTION; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STANDARD PERIPROCEDURAL THERAPY; STROKE; THERAPY; UPFRONT DRUG ADMINISTRATION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; CZECH REPUBLIC; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; SHOCK, CARDIOGENIC; STROKE VOLUME; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80052515285     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.3109/17482941.2011.567282     Document Type: Article

References (28)

1. Babaev A.,Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005. 294: 448-54.
2. H ochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;241:625-34.
3. J eger RV, Radovanovic D, Hunziker PR, Pfi sterer ME, Stauff er JC, Erne P., et al. Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med. 2008;149:618-26.
4. Chan AW, Chew DP, Bhatt DL, Moliterno DJ, Topol EJ, Ellis SG. Long-term mortality benefi t with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol. 2002;89:132-6.
5. Giri S, Mitchel J, Azar RR, Kiernan FJ, Fram DB, McKay RG., et al. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol. 2002;89:126-31.
6. A ntoniucci D, Valenti R, Migliorini A, Moschi G, Trapani M, Dovellini EV., et al. Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol. 2002;90:353-7.
7. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ., et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. A report from the American Society of Echocardiography's guidelines and standards committee and the task force on echocardiography in clinical trials. J Am Soc Echocardiog. 2004;17: 1086-119.
8. Th ygesen K, Alpert JS, Harvey D. Universal defi nition of myocardial infarction. Eur Heart J. 2007;28:2525-2538.
9. M ehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG., et al. Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.
10. Parikh CR, Coca SG, Wang Y, Masoudi FA, Krumholz HM. Long-term prognosis of acute kidney injury aft er acute myocardial infarction. Arch Intern Med. 2008;168:987-95.
11. Rao AK, Pratt C, Berke A, Jaff e A, Ockene I, Schreiber TL., et al. Th rombolysis in myocardial infarction (TIMI) trial - phase I: Hemorrhagic manifestations and changes in plasma fi brinogen and the fi brinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
12. De Luca G, Suryapranata H, Stone G, Antoniucci D, Tcheng JE, Neumann FJ et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction. JAMA 2005;293:1759-65.
13. M ontalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Miglorini A., et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: A European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J. 2007;28:443-9.
14. Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ., et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 2002;113:1-6.
15. A nderson KM, Califf RM, Stone GW, Neumann FJ, Montalescot G, Miller DP., et al. Long-term mortality benefi t with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2001;37:2059-65.
16. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percu taneous coronary intervention of acute ST-segment elevation myocardial infarction. JAMA 2004;292: 362-6.
17. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: Quantitative review of randomized trials. Lancet 2006;367:579-88.
18. E llis SG, Tendera M, de Belger MA, van Boven AJ, Widimsky P, Janssens L., et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358:2205-17.
19. Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N., et al. Long-term eff ectiveness of early administration of glykoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: Results of registry study in an ST-elevation myocardial infarction network. Eur Heart J. 2009;30:33-43.
20. H uber K, Holmes DR Jr, van't Hof AW, Montalescot G, Aylward PE, Betriu GA., et al. Use of glykoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: Insight from the APEX-AMI Trial. Eur Heart J. 2010;31:1708-16.
21. D e Luca G, Gibson CM, Bellandi F, Murphy S, Maioli M, Noc M., et al. Early glycoprotein IIb-IIa inhibitors in primary angioplasty (EGYPT) cooperation: An individual patient data meta-analysis. Heart 2008;94:1548-58.
22. De Luca G, Suryapranata H, Zijlstra F, van't Hof AW, Hoorntje JC, Gosselink AT., et al. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 2003;42:991-7.
23. Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ., et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283: 2941-7.
24. G ersh BJ, Stone GW, White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: Is the slope of the curve the shape of the future? JAMA 2005;293:979-86.
25. V an de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Th e task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909-45.
26. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J ., et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients.GUSTO-I investigators. Circulation 1995;91:1659-68.
27. S teg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, López-Sendón J., et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: Observations from the global registry of acute coronary events (GRACE). Circulation 2004;109:494-9.
28. Wu AH, Parson L, Every NR, Bates R. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: A report from the second national registry of myocardial infarction (NRMI-2). J Am Coll Cardiol. 2002;40:1389-94.